期刊
JOURNAL OF CLINICAL INVESTIGATION
卷 105, 期 3, 页码 287-292出版社
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI8538
关键词
-
资金
- NICHD NIH HHS [R01 HD027183, HD-27183] Funding Source: Medline
- NIDDK NIH HHS [R01 DK033651, DK-33651, R37 DK033651] Funding Source: Medline
The thiazolidinedione class of insulin-sensitizing, antidiabetic drugs interacts with peroxisome proliferator-activated receptor gamma (PPAR-gamma). To gain insight into the role of this this nuclear receptor in insulin resistance and diabetes, we conducted metabolic studies in the PPAR-gamma gene knockout mouse model. Because homozygous PPAR-gamma-null mice die in development, we studied glucose metabolism in mice heterozygous for the mutation (PPAR-gamma mice). We identified no statistically significant differences in body weight, basal glucose, insulin, or FFA levels between the wild-type (WT) and PPAR-gamma(+/-) groups. Nor was there a difference in glucose excursion between the groups of mice during oral glucose tolerance test, but insulin concentrations of the WT group were greater than those of the PPAR-gamma(+/-)group, and insulin-induced increase in glucose disposal rate was significantly increased in PPAR-gamma(+/-)mice. Likewise, the insulin-induced suppression of hepatic glucose production was significantly greater in the PPAR-gamma(+/-) mice than in the WT mice. Taken together, these results indicate that - counterintuitively - although pharmacological activation of PPAR-gamma improves insulin sensitivity, a similar effect is obtained by genetically reducing the expression levels of the receptor.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据